CJ Bioscience
Financials
Valuation Metrics
CJ Bioscience's Market Cap is ₩482B. At end of 2025 it was ₩1218B. Ranked #1738 of 2,405 in KR market (top 72%), #1053 of 1,627 on KOSDAQ (top 65%), #70 of 94 in Health Care Equipment & Services (top 74%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 48.21B KRW | KR#1,738/2,405 Sec#70/94 |
| Revenue | 3.68B KRW | KR#2,341/2,405 Sec#89/94 |
| Net Income | -22.33B KRW | KR—/2,405 Sec—/94 |
| Total Assets | 60.39B KRW | KR#2,096/2,405 Sec#68/94 |
| Net Assets | 41.75B KRW | KR#2,015/2,405 Sec#69/94 |
| Employees | 129 | KR#1,442/2,405 Sec#51/94 |
| Value | ||
| P/B | 1.15x | KR#1,644/2,405 Sec#51/94 |
| P/S | 13.11x | KR#2,300/2,405 Sec#85/94 |
| FCF Yield | -48.59% | KR—/2,405 Sec—/94 |
| Profitability | ||
| ROE | -53.48% | KR#2,271/2,405 Sec#86/94 |
| ROA | -36.97% | KR#2,326/2,405 Sec#88/94 |
| Op. Margin | -624.86% | KR#2,355/2,405 Sec#93/94 |
| Revenue Growth | 8.72% | KR#962/2,405 Sec#51/94 |
| Financial Health | ||
| Debt Ratio | 44.66% | KR#877/2,405 Sec#49/94 |
| Total Debt | 7.88B KRW | KR#1,684/2,405 Sec#51/94 |
| FCF | -23.43B KRW | KR#1,922/2,405 Sec#73/94 |
| Cash | 4.56B KRW | KR#2,026/2,405 Sec#73/94 |
| Current Ratio | 2.88x | KR#583/2,405 Sec#35/94 |
| Performance | ||
| 1Y Return | -59.72% | KR#2,149/2,405 Sec#82/94 |
| 1M Return | -2.25% | KR#475/2,405 Sec#17/94 |
| From 52W High | -63.82% | KR#1,831/2,405 Sec#66/94 |
| 1Y MDD | -67.89% | KR#1,856/2,405 Sec#65/94 |
| Trading | ||
| Volume | 9,860 shares | KR#1,851/2,405 Sec#75/94 |
| Trading Value | 36.7M KRW | KR#1,875/2,405 Sec#75/94 |
| Foreign Own. | 2.77% | KR#1,361/2,405 Sec#46/94 |
| Per Share | ||
| EPS | -1,709 KRW | KR—/2,405 Sec—/94 |
| BPS | 3,195 KRW | KR#1,827/2,405 Sec#56/94 |
Company Info
CJ Bioscience, a microbiome specialized company, was established in 2009 and listed on the KOSDAQ market in 2019. The company engages in therapeutic new drug development via its Artificial Intelligence-based microbiome big data platform, bioinformatics analysis services, and customized healthcare solutions. It offers new drug candidate material analysis based on the Ez-Mx® platform, microbial genome analysis utilizing EzBioCloud and N integrated solutions, and customized healthcare services leveraging a human microbiome database of over 140,000 cases. CJ Bioscience is headquartered in Jung-gu, Seoul.